New intranasal corticosteroid

GlaxoSmithKline has launched a new intranasal corticosteroid, Avamys, for the treatment of allergic rhinitis in adults and children over six years old.

Each spray actuation delivers 27.5 micrograms of fluticasone furoate.

View Avamys drug record

Further information: GlaxoSmithKline

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Antibiotic Treatments in Adults, Summary of Regimens

Antibiotic Treatments in Adults, Summary of Regimens

Dose regimens for common bacterial infections.

Be vigilant for suspected e-cigarette or vaping-associated lung injury, MHRA advises

Be vigilant for suspected e-cigarette or vaping-associated lung injury, MHRA advises

The MHRA has advised clinicians to have a high index...

Actinic keratosis treatment recalled due to growing skin cancer concerns

Actinic keratosis treatment recalled due to growing skin cancer concerns

Healthcare professionals have been advised to stop...

PHE issues coronavirus guidance for primary care

PHE issues coronavirus guidance for primary care

Public Health England (PHE) has issued guidance for...